Would it be reasonable to offer a patient with CLL a treatment break from acalabrutinib or any BTK inihibitor after a period of time, assuming good response?   

It is understood that the trial's experience was to keep on treatment indefinitely until progression or unacceptable toxicity. We are asking about real world experience here, where financial toxicity and "acceptable toxicity" are real things patients still suffer from.

Answer from: Medical Oncologist at Academic Institution